SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for Clinical Trial NCT01002898

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Treatment Outcomes and Plasma Level of Ritonavir-boosted Lopinavir Monotherapy Among HIV-infected Patients Who Had Non-nucleoside Reverse Transcriptase Inhibitor (NRTI) and NNRTI Failure: A Pilot Study

To assess 48-week treatment responses, tolerability, and steady-state minimum plasma concentrations of ritonavir-boosted lopinavir monotherapy for salvage therapy in HIV-1 infected patients who failed antiretroviral regimens containing NRTI and NNRTI.

NCT01002898 HIV

1 Interventions

Name: lopinavir/ritonavir soft gel capsule

Description: Ritonavir-boosted lopinavir in soft gel formulation at 400/100 mg and lamivudine at 150 mg were given twice daily.
Type: Drug
Group Labels: 1


Primary Outcomes

Measure: To assess 48-week treatment responses of ritonavir-boosted lopinavir (LPV/r) monotherapy as salvage regimen.

Time: 48 weeks

Purpose: Treatment

Allocation: Non-Randomized

Single Group Assignment

There is one SNP


1 M184V

Inclusion Criteria: 1. HIV-1 infected patients >18 years of age, 2. failed NNRTI-based antiretroviral therapy with M184V, thymidine analogue mutations (TAMs) and NNRTI-associated mutations 3. had plasma HIV-1 RNA >1,000 copies/mL. --- M184V ---

On the other hand, previous studies showed that continuation of lamivudine after emerging of the M184V mutation had somewhat benefit on immunological response and clinical progression in patients who had limited options of salvage regimens. --- M184V ---

HPO Nodes